Anaplastic lymphoma kinase (ALK) is one of the common oncogenic driver genes in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have achieved excellent therapeutic effects in patients with ALK fusion positive NSCLC. However. patients will eventually develop resistance to TKIs. https://www.roneverhart.com/Asus-ROG-Zephyrus-GU502LV-BI7N8-15-6-4K-3840x2160-IPS-Intel-i7-10750H-2-6-GHz-16GB-1TB-SSD-NVIDIA-GeForce-RTX-2060-6G/